Table 1.
Baseline demographics and perioperative procedures for proliferative diabetic retinopathy patients undergoing vitrectomy by surgical indication.
| VMI abnormalities (N=120) | TRD (N=326) | Combined TRD and RRD (N=129) | VH (N=315) | P value | |
|---|---|---|---|---|---|
| Mean age (SD), year | 56.9 (8.9) | 49.3 (9.8) | 51.1 (9.5) | 52.9 (10.3) | <0.001 |
| Gender, male/female | 52/68 | 116/210 | 41/88 | 145/170 | 0.009 |
| Type II diabetes, N (%) | 116 (96.7) | 306 (93.9) | 122 (94.6) | 300 (95.2) | 0.699 |
| Baseline VA (SD), logMAR unit | 1.0 (0.4) | 1.6 (0.6) | 1.6 (0.7) | 1.7 (0.7) | <0.001 |
| 23G PPV, N (%) | 69 (57.5) | 139 (42.6) | 70 (54.3) | 156 (49.5) | 0.017 |
| Combined primary PPV and cataract surgery, N (%) | 42 (35.0) | 67 (20.6) | 23 (17.8) | 79 (25.1) | 0.006 |
| Preoperative intravitreal bevacizumab injection within 4 weeks prior to and/or at the end of PPV, N (%) | 54 (45.0) | 180 (55.2) | 59 (45.7) | 186 (59.0) | 0.122 |
| Primary intraoperative silicone oil tamponade, N (%) | 0 (0) | 109 (33.4) | 75 (58.1) | 7 (2.2) | <0.001 |
VMI = vitreomacular interface abnormalities; VH = vitreous hemorrhage; TRD = tractional retinal detachment; RRD = rhegmatogenous retinal detachment; SD = standard deviation; VA = visual acuity; VEGF = vascular endothelial growth factor; PPV = pars plana vitrectomy.